Feasibility and safety of accelerated MVAC (aMVAC) in geriatric patients with muscle-invasive bladder cancer
Authors:
- Sai PrasathSPSai Prasath
- Deepak SundriyalDSDeepak Sundriyal
- S P HarshaSHS P Harsha
- Anusha Mruthyunjaya SwamyASAnusha Mruthyunjaya Swamy
- Karthik JayalingappaKJKarthik Jayalingappa
- Mayank KapoorMKMayank Kapoor
- Mahesh KoulagiMKMahesh Koulagi
- Vikas Kumar PanwarVPVikas Kumar Panwar
- Ankur MittalAMAnkur Mittal
- Amit SehrawatASAmit Sehrawat
- 20 August 2026
- journal article
- research article
- Published by Springer Nature in Medical Oncology
- Vol. 43 (9) , 248
Abstract
Dose-dense MVAC (ddMVAC) is a standard regimen for muscle-invasive bladder cancer (MIBC), but tolerability concerns often limit its use in geriatric patients. Accelerated MVAC (aMVAC), delivered as a single-day regimen, may reduce hospital visits and resource use. This study assessed the feasibility and safety of aMVAC in geriatric patients with MIBC in a real-world, resource-constrained setting. We included patients aged 60 years or older with histologically confirmed MIBC (stages II–IV). Eligible patients received three or four cycles of single-day aMVAC (methotrexate 30 mg/m², vinblastine 3 mg/m², doxorubicin 30 mg/m², cisplatin 70 mg/m²) every 14 days, with growth factor support. Feasibility was defined as completing 3 or 4 cycles within the protocol-defined duration. Toxicities were graded per CTCAE v5.0. Among 33 geriatric patients, 30 (90.9%) completed ≥ 3 cycles, and 28 (84.8%) completed four cycles within the planned timeframe. Dose reductions for grade 3 or higher toxicities were required in 10 (30.3%) patients, and treatment discontinuation occurred in 3 (9%). Grade 3 hematologic events occurred in 12% and non-hematologic events in 33.3%; the most common were anemia, mucositis, and fatigue. No grade 4 toxicities, febrile neutropenia, or treatment-related deaths were observed. Pathological complete response (pCR; ypT0N0) was achieved in 8 (36.4%) patients, and 12 (54.5%) patients had pathologic down-staging compared with their clinical stage. aMVAC is a feasible regimen for geriatric patients with MIBC, achieving high treatment completion rates and acceptable toxicity. The simplified one-day protocol reduces hospital stay and logistical burden while maintaining therapeutic intensity. aMVAC represents a practical and feasible alternative in real-world, resource-limited settings. Clinical Trial Registration The trial was registered under clinical trial registry of India : CTRI/2021/10/037450.Keywords
This publication has 14 references indexed in Scilit:
- Management of Locally Advanced Unresectable or Metastatic Urothelial Carcinoma: Expert Opinion from an Indian Panel via Delphi Consensus MethodIndian Journal of Medical and Paediatric Oncology, 2023
- Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER TrialJournal of Clinical Oncology, 2022
- The global burden of urinary bladder cancer: an updateWorld Journal of Urology, 2019
- Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric OncologyJournal of Clinical Oncology, 2018
- Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and ToxicityJournal of Clinical Oncology, 2014
- Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker CorrelatesJournal of Clinical Oncology, 2014
- Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle‐invasive transitional cell carcinoma of the bladderCancer, 2012
- Exclusion of Older People from Clinical TrialsDrugs & Aging, 2011
- Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based ChemotherapyJournal of Clinical Oncology, 2011
- Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III StudyJournal of Clinical Oncology, 2000